Researchers at Roche Molecular Diagnostics will use Partek GS to analyze diagnostic data from a variety of studies involving drug development. Current research at Roche involves using biomarkers to determine patients’ reactions to specific medications, as well as drug discovery. Roche, a leader in the pharmaceutical industry, has provided such therapeutic drugs as Tamiflu®, Herceptin®, and Boniva®.
Partek GS allows for thorough analysis of gene expression, exon alternative splicing, copy number, genome-wide SNP, and ChIP-chip regulation data within in the same software package. In addition, Partek GS provides easy to use workflows to walk through the analysis process. Partek GS is Affymetrix GeneChip-compatibleTM for gene expression analysis, exon expression analysis, chromosomal copy number analysis, tiling array analysis, and chromosomal copy number analysis of high density SNP arrays.
Partek Incorporated is a leading provider of statistical analysis and interactive data visualization software for the scientific research community. Partek software enables researchers to quickly identify and quantify patterns in data, including data resulting from genomic and proteomic studies, high-throughput screening campaigns, and computer aided drug design. Partek is located in St. Louis, Missouri.